Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
92.28 EUR | +2.77% |
|
+1.59% | +1.91% |
04:26pm | Sanofi eyes German insulin investment of up to $1.6 bln, source says | RE |
03:21pm | Sector Update: Health Care Stocks Mixed Premarket Monday | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The company returns high margins, thereby supporting business profitability.
- The company is in a robust financial situation considering its net cash and margin position.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- Analyst opinion has improved significantly over the past four months.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
Weaknesses
- For the past year, analysts have significantly revised downwards their profit estimates.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+1.91% | 120B | - | ||
+56.56% | 815B | C+ | ||
+43.79% | 641B | B | ||
-6.31% | 352B | C+ | ||
+17.79% | 314B | B- | ||
+10.63% | 303B | C+ | ||
+16.11% | 242B | B+ | ||
+2.29% | 224B | A+ | ||
+13.84% | 218B | B- | ||
+8.63% | 168B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- SAN Stock
- SNW Stock
- Ratings Sanofi